Caribou Biosciences, Inc. (NASDAQ:CRBU) Given Consensus Recommendation of "Buy" by Brokerages

Shares of Caribou Biosciences, Inc. (NASDAQ:CRBU - Get Free Report) have been assigned a consensus rating of "Buy" from the five analysts that are currently covering the firm, MarketBeat reports. Five equities research analysts have rated the stock with a buy recommendation. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $10.33.

A number of research analysts recently commented on the stock. Citigroup decreased their price target on shares of Caribou Biosciences from $30.00 to $6.00 and set a "buy" rating on the stock in a research note on Tuesday, November 26th. HC Wainwright reiterated a "buy" rating and set a $9.00 price objective on shares of Caribou Biosciences in a research report on Friday, November 15th. Finally, Bank of America reduced their target price on shares of Caribou Biosciences from $13.00 to $11.00 and set a "buy" rating for the company in a research report on Tuesday.

Caribou Biosciences Trading Down 0.5 %

Shares of Caribou Biosciences stock traded down $0.01 during trading on Tuesday, hitting $1.87. 1,732,505 shares of the stock were exchanged, compared to its average volume of 1,470,776. The company has a fifty day moving average price of $2.03 and a 200-day moving average price of $2.00. The stock has a market capitalization of $169.33 million, a price-to-earnings ratio of -1.13 and a beta of 2.34. Caribou Biosciences has a 1-year low of $1.50 and a 1-year high of $8.33.

Caribou Biosciences (NASDAQ:CRBU - Get Free Report) last posted its earnings results on Wednesday, November 6th. The company reported ($0.38) earnings per share for the quarter, topping analysts' consensus estimates of ($0.44) by $0.06. Caribou Biosciences had a negative return on equity of 45.46% and a negative net margin of 1,290.81%. The business had revenue of $2.02 million for the quarter, compared to analyst estimates of $3.37 million. Equities research analysts forecast that Caribou Biosciences will post -1.64 EPS for the current fiscal year.

Institutional Investors Weigh In On Caribou Biosciences

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Erste Asset Management GmbH bought a new stake in shares of Caribou Biosciences during the third quarter worth $28,000. AQR Capital Management LLC acquired a new stake in shares of Caribou Biosciences during the 2nd quarter valued at $30,000. China Universal Asset Management Co. Ltd. increased its holdings in Caribou Biosciences by 63.8% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 17,380 shares of the company's stock worth $34,000 after purchasing an additional 6,768 shares in the last quarter. Intech Investment Management LLC bought a new position in Caribou Biosciences in the third quarter valued at about $43,000. Finally, Point72 DIFC Ltd boosted its stake in shares of Caribou Biosciences by 389.4% during the second quarter. Point72 DIFC Ltd now owns 30,157 shares of the company's stock valued at $49,000 after purchasing an additional 23,995 shares in the last quarter. 77.51% of the stock is owned by institutional investors.

About Caribou Biosciences

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.